Omeros' oms906 data presented at complement-based drug development summit

Seattle--(business wire)--omeros corporation (nasdaq: omer) presented data from its oms906 program yesterday at the 4th complement-based drug development summit. oms906 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (masp-3), the key activator of the complement system's alternative pathway. the presentation about the inhibition of the alternative pathway by targeting masp-3 was made by jason cummings, ph.d., omeros' associate directo
OMER Ratings Summary
OMER Quant Ranking